COVID-19, the disease caused by the newly merging coronavirus (SARS-COV2) is a major health concern worldwide currently ( Zhang et al., 2020). The pandemic is unprecedented in recent history and a lot of restrictions were imposed across the globe in an attempt to contain the spread of the infection hoping to reduce the number of carriers and, consequently, the fatality rates. This, in turn will relieve the pressure on health authorities. The outbreak has spread rapidly from its start point in the mainland of China to more than 200 countries, according to World Health Organization figures ( Zhou et al., 2020). The large number of patients who need medical care, especially those with an immediate requirement of intensive care and hospitalization resulted in overwhelming the financial, manpower and the managerial facets of healthcare centers and represented a huge burden on states ( Zhang et al., 2020).

Data available so far indicates a remarkable quick spread of the virus, suggesting a high infectivity in comparison to SARS-COV of the same genus ( Zhou et al., 2020). Regarding the virus spread, SARS-COV2, which causes COVID-19, can be transmitted via direct contact with infected surfaces or airborne droplets. Vertical transmission was not proven so far, therefore, transmission of the virus to babies from mothers is unlikely, according to the available evidence ( Zhu et al., 2020). It was also reported that SARS-COV2 has a higher morbidity and mortality, and higher fatality rates than SARS-COV. At this end, COVID-19 patients suffer from severe suppression of cellular-mediated immune response to the virus as evident by the low count of CD3 ⁺, CD4 ⁺, and CD8 ⁺ cells ( Chen et al., 2020). In this respect, SARS-COV, downregulates interferon (IFN) regulatory factor 3 (IRF-3), which ameliorates the antiviral activity mediated by IFN α and β axis; this scenario might also contribute to the suppression of antiviral activity in COVID-19 patients ( Kuri and Weber, 2010). In a similar respect, early reports this year indicated that SARS-COV2 is detectable in clinical samples of non-survivors throughout the clinical course of the disease ( Weiss and Murdoch, 2020). Moreover, an American study postulated that ethnicity and gender differences might have a potential influence on hospitalization and mortality of COVID-19 patients ( Price-Haywood et al., 2020).

The aim of the current study was to provide up to date simple statistical estimates and insights into the official numbers published by the Saudi Ministry of Health and establish an overview to understand the epidemiological data of COVID-19 in the Kingdom of Saudi Arabia. This might help to set future action plans to improve the overall outcomes of disease management.

This is a data-based study in which the official data on COVID-19 disease that were published by the Saudi Ministry of Health on COVID-19 dashboard were analyzed. Data are available from: https://covid19.moh.gov.sa/. The data published on the dashboard are presented as graphs showing the numbers of confirmed cases, recovered cases and deaths day by day. The numbers are updated on a daily basis.

The following data were extracted from the dashboard for this study: minimum and maximum numbers for confirmed cases of COVID-19, recovered cases of COVID-19, and deaths relating to COVID-19 reported for March-November 2020 The total number of people living in Saudi Arabia was determined according to the estimates of the United Nations that were published on the Worldometer website: https://www.worldometers.info/.

The total number of deaths in each month and case fatality rates were compared between the months in 2020, and death rates/1000 of the population were calculated. Regression analysis was also performed to underline the relationship between different figures reported for each month including the relationships between: (1) the number of confirmed cases (daily reported infections in each month) and the number of the recovered cases (daily reported recoveries in each month), and (2) the number of confirmed cases and the number of monthly reported COVID-19-related deaths (daily reported deaths in each month).

Statistical presentations and calculations were performed using Graphpad Prism (version 7). The data were tested for normality and the Kruskal Wallis test was employed for comparison between groups, followed by Dunn’s multiple comparison test. The difference was considered statistically significant at p ≤ 0.05.

Table 1 shows the minimum and maximum numbers recorded for COVID-19 confirmed cases, recovered cases and deaths for each month of 2020. The maximum numbers of confirmed cases were recorded during June, while the maximum recovered cases and deaths were recorded in July. There was an increase in the number of confirmed cases from March-June, and then the numbers started to decrease during July-November. The low number recorded in the first one or two months might be associated with the total number of performed tests, where the capacity of health authorities worldwide may not have been fully prepared for such a surprising pandemic.

As the recently emerging pandemic of COVID-19 continues to attract attention all over the world with uncertainty about when the disease will vanish and cease new waves, the need continues to grow to assess the capacity of health care authorities to cope with the current challenge and be ready for all possibilities. In this respect, the assessment of the past and present situation data is important for accurate need assessment for future preparation. Therefore, the main aim of the current study was to analyze the data to conclude some statistical figures that could help to understand how effective the management of the situation was, and what should we do for better clinical management outcomes of the COVID-19 crisis. The results showed that the numbers of confirmed deaths reached the peak during June and July, with the highest death rates/1000 of the population. Also, despite the decrease in the number of the confirmed deaths in September-November, the case fatality rates were the highest throughout the period from March-November, which also showed a small number of confirmed cases that might have resulted in the high case fatality rate. The world is still overwhelmed with the pandemic; however, the situation seems to be under control in Saudi Arabia, despite the high case fatality rates recorded in September-November. Case fatality could be affected with multiple factors, such as patients’ age, comorbidities or virus virulence and immune response efficacy in patients. To this end, other data, such as patients’ demographics, comorbidities, medical history, autopsy reports and detailed lab records and clinical follow up data should be available for a more comprehensive figure. In this regard, it was reported that up to 81% of COVID-19 patients might suffer only from a mild disease, which does not require hospitalization ( Price-Haywood et al., 2020). Having said that, the other 19%, which is a proportion large enough to overwhelm the health care sector, might suffer from severe symptoms that impose hospitalization and here is where mortality rates could increase as a result of poor clinical management.

It was also recently reported that the average case fatality rate of COVID-19 is less than 5% ( Sun et al., 2020). This estimate suggests that the case fatality rates reported in the current study are within the global figures. The surprising hit of the pandemic and/or the virulence of the virus strain and its quick spread needed some time for the governments to confine the situation. In this regard, many comorbidities were linked to the increased severity and mortality of COVID-19 patients, including diabetes mellitus ( Kumar et al., 2020). It is of importance to denote that diabetes mellitus is prevalent in Saudi Arabia ( Alotaibi et al., 2017). However, more data should be available on COVID-19 casualties before assuming any link between the disease and COVID-19 mortality figures presented herein. It might be also of importance to mention that the case fatality rates of COVID-19 are lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) ( Sun et al., 2020), but we have to bear in mind that the number of cases of COVID-19 patients is much higher than that recorded for the other two counterparts. Similar case fatality rates were reported for both China and Italy (~2.3) at the beginning of the pandemic, with comorbidities that might have contributed significantly to mortality in elderly patients ( Porcheddu et al., 2020). These figures are almost similar to the average case fatalities reported in the period (March-September) in Saudi Arabia. In line with the current study, Boretti compared some figures of the outbreak between Saudi Arabia and the United Kingdom in the middle of the outbreak; Boretti reported that the number of cases per million, the number of deaths per million and the number of newly daily deaths per million were much less in Saudi Arabia than those in the United Kingdom ( Boretti, 2020).

In order to give a brief account on the figures post vaccination campaign, the case fatality rates were calculated from the officially published figures in the first 6 months in 2021 (January-June). The number of newly recorded cases escalated from ~5000 cases in January to ~37000 in June. This means that following flattening of the curve at the end of 2020, there was an ascending increase in the number of cases again after the start of the vaccination campaign. However, the number of cases still much less than the numbers recorded in the same months in 2020 before vaccination. The case fatality rate in January 2021 was 0.03 (3%), whilst that calculated for February-June was 0.01 (1%), which is similar to that recorded for June 2020; however, there was a clear reduction in the number of confirmed cases and deaths in 2021. Whether the reduction in confirmed cases and deaths numbers is due to vaccination or other factors, this is not confirmed due to lack of information about the number of vaccinated people who contracted the infection nor those who died after being vaccinated. Therefore, we have to wait the release of all official figures and information before we make a final conclusion about the efficacy of vaccination.

In conclusion, the results presented in the current study suggested that the fatality rates of COVID-19 mortality and their association with the number of confirmed cases and the recovery figures should be always seen in the same frame with the absolute figures to reflect the real situation to the policy makers for better needs assessment, future planning and prompt response in crisis time. Amongst the limitations of the current study, and maybe other related published articles, are the lack of information on cases and deaths age groups, comorbidities, ethnicity, and medical history that might have affected disease progression and mortality rates. The availability of such information could help to clarify risk factors and those predisposed for a severe disease clinical course. Also, we have to bear in mind that the number of COVID-19 cases are much higher than that of the disease counterparts SARS and MERS when we look at the fatality rates.

All data presented herein were extracted by analyzing the publicly available data on COVID-19 that were uploaded to the COVID-19 data portal established by the Saudi Ministry of Health: https://covid19.moh.gov.sa/.